Sibeprenlimab targets a protein called A proliferation-inducing ligand (APRIL), and the drug is designed to limit the ...

Atacicept met its Phase 3 proteinuria reduction endpoint, supporting optimism for Vera's accelerated FDA approval filing ...

Novartis’ $1.7 billion Regulus Therapeutics buyout last month came after a hard-fought battle in which the Swiss pharma and ...

Researchers found that nearly 28% of hospitalized chronic liver disease patients with acute kidney injury had alcohol-related disorders, as did almost 60% with hepatorenal syndrome.

Final draft guidance from NICE has backed NHS use of Filspari (sparsentan) for primary immunoglobulin A nephropathy (IgAN), ...

The U.S. FDA approved 20 drugs for market in April, slightly down from 22 in March, 16 in February and 12 in January. This brings the total number of FDA approvals for the first four months of 2025 to ...

Atrasentan (Vanrafia) was approved in 2025 for the treatment of IgAN in people who are at risk of their disease getting worse quickly. It belongs to a class of medicines called endothelin receptor ...

Pluvicto, Vanrafia, and Fabhalta, all achieved approvals in their relevant indications. We had a global submission for remibrutinib and CSU and our OAV-101 IT gene therapy for patients with SMA ...

In early April, Novartis drug Vanrafia won accelerated FDA approval as a treatment for immunoglobulin A nephropathy (IgAN). That small molecule came from the $3.2 billion acquisition of Chinook ...

Novartis to acquire Regulus for $7/share upfront, a 108% premium to April 29 close and 274% over 60-day VWAP. The total deal could reach $1.7 billion if farabursen gains regulatory approval, with ...